D04AX01 doxepin
DERMATOLOGICALS ›ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ›ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ›Other antipruritics
非健保收載 FDA 已核准 TFDA 在效許可證 1 健保給付條款 1
FDA 適應症
INDICATIONS AND USAGE Doxepin Hydrochloride Capsules, USP are recommended for the treatment of: 1. Psychoneurotic patients with depression and/or anxiety. 2. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). 3. Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). 4. Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age.
資料來源:openFDA(美國 FDA Structured Product Labeling)。為英文原文,僅供對照。
TFDA 適應症
NHI 給付規定
直接適用條款
§ 13.7 Doxepin HCl cream (如Ichderm):(88/6/1)
皮膚科製劑 › Doxepin HCl cream (如Ichderm):(88/6/1)
Doxepin HCl cream (如Ichderm):(88/6/1) 限成人使用,每次處方不超過七天。
歷史演變(1 次異動)
| 生效日 | 異動說明 |
|---|---|
| 88/6/1 | legacy_boan_parsed:ch13.txt |
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
FDA 段:openFDA US SPL · TFDA 段:食藥署西藥許可證+ATC 分類開放資料 · NHI 段:健保署「全民健康保險藥品給付規定」(更新日 2026-05-31)· 實證補充段:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。